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Abstract
Background: Hepatic lipidosis or fatty liver disease is a major metabolic disorder of high-producing dairy cows that
compromises animal performance and, hence, causes heavy economic losses worldwide. This syndrome, occurring
during the critical transition from gestation to early lactation, leads to an impaired health status, decreased milk
yield, reduced fertility and shortened lifetime. Because the prevailing clinical chemistry parameters indicate advanced
liver damage independently of the underlying disease, currently, hepatic lipidosis can only be ascertained by liver
biopsy. We hypothesized that the condition of fatty liver disease may be accompanied by an altered profile of endogenous
metabolites in the blood of affected animals.
Results: To identify potential small-molecule biomarkers as a novel diagnostic alternative, the serum samples of
diseased dairy cows were subjected to a targeted metabolomics screen by triple quadrupole mass spectrometry.
A subsequent multivariate test involving principal component and linear discriminant analyses yielded 29 metabolites
(amino acids, phosphatidylcholines and sphingomyelines) that, in conjunction, were able to distinguish between dairy
cows with no hepatic lipidosis and those displaying different stages of the disorder.
Conclusions: This proof-of-concept study indicates that metabolomic profiles, including both amino acids and lipids,
distinguish hepatic lipidosis from other peripartal disorders and, hence, provide a promising new tool for the diagnosis
of hepatic lipidosis. By generating insights into the molecular pathogenesis of hepatic lipidosis, metabolomics studies
may also facilitate the prevention of this syndrome.
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Background
Hepatic lipidosis (also known as “fatty liver disease” or
“fat cow syndrome”) is a common production problem
of dairy cows occurring during the critical physiologic
transition from pregnancy to lactation [1-3]. During the
last decades, dairy cows have undergone an intense gen-
etic selection to increase the milk yield, thereby reaching
an enhanced performance level where the excessive de-
mand for nutrients results in a severe energetic deficit at
the onset of lactation [4-6]. A major adjustment to coun-
teract this metabolic imbalance is the rapid mobilization
of fat depots, thus providing non-esterified fatty acids as
an energy source. Hepatic lipidosis develops when, during
early lactation, the hepatic uptake of these non-esterified
fatty acids and storage in the form of triacylglycerols ex-
ceeds their elimination [2,7]. The rate of triacylglycerol
production in the liver tissue of ruminants is similar to
that found in other species [8]. However, besides their use
for energy production through mitochondrial breakdown
by oxidation, triacylglycerols are released from hepato-
cytes as part of lipoproteins, whereby very low-density
lipoproteins (VLDL) constitute the largest proportion. In
ruminants, the secretion of VLDL from the liver is very
limited compared with other species such that the result-
ing storage of excess lipids in hepatocytes leads to liver
damage and depressed liver functions [8,9].
Hepatic lipidosis in cows is associated with ketosis, an-
orexia, reduced rumen motility, displaced abomasum,
weight loss, predisposition to infections and diminished
fertility [10,11], although the disease also occurs in a
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subclinical form affecting milk production and the long-
term profitability of dairy farms. Indeed, previous reports
suggest that this syndrome is a substantial problem for
up to 50% of high-yielding cows [12,13] and, hence, hep-
atic lipidosis is recognized as a serious herd problem
and animal welfare concern. Unfortunately, the diagnosis
of hepatic lipidosis can only be confirmed by taking
biopsies to determine the hepatic lipid content [8]. Bio-
chemical abnormalities like increased liver enzymes and
bilirubin concentrations in plasma correlate with ad-
vanced tissue damage but are not specific for hepatic lip-
idosis [14]. Thus, in view of the lack of a practically
useful diagnostic tool, we explored an alternative strat-
egy by screening for small-molecule biomarkers. The
purpose of this study was to identify serum biomarkers
that distinguish cows with hepatic lipidosis from those
affected by other peripartal disorders.
Methods
Animal samples
Blood samples were taken from the jugular vein of
Holstein-Friesian and Red-Holstein cows that contracted
hepatic lipidosis or other diseases that typically occur dur-
ing the peripartal period, including displaced abomasum,
retained placenta or mastitis (Table 1). Plasma for clinical
chemistry was prepared by supplementing blood samples
with either heparin or EDTA. For metabolomic analyses,
serum was collected and stored at −80°C. The diagnosis of
hepatic lipidosis was obtained by liver biopsy and histo-
logic inspection. The stage of disease was classified as de-
scribed [15] according to the different extension of lipid
deposition across the morphologic liver zones (periportal,
transition zone and pericentral): group 1 (no lipid depos-
ition), group 2 (only one zone affected), group 3 (all three
zones affected), group 4 (Kupffer cells affected in addition
to all three zones). Ethics approval was not requested and
not needed because samples were taken from diseased an-
imals during routine diagnostic investigations when hep-
atic lipidosis was suspected in peripartal dairy cows.
Clinical chemistry
Biochemical parameters were determined in plasma using
the Cobas Integra 800 instrument (Roche Diagnostic,
Rotkreuz, Switzerland). Aspartate aminotransferase (ASAT)
was measured according to recommendations of the
International Federation of Clinical Chemistry [16] with
intra-assay and inter-assay coefficients of variance (CV)
of 1.4% and 1.7%, respectively; γ-glutamyl transferase
(GGT) was measured by a colorimetric assay [17] with
intra-assay and inter-assay CV of 1.8%; further colori-
metric assays [18,19] were employed for the determin-
ation of glutamate dehydrogenase (GLDH) and sorbitol
dehydrogenase (SDH) activities. For GLDH, the intra-
assay and inter-assay CV were 0.8% and 1.2%, respectively;
the intra-assay and inter-assay CV for SDH measurements
were 3.9% and 3.2%. Bilirubin levels (intra-assay CV of
2.4%) were assessed by a diazo method [20]. Total protein
(intra-assay CV and inter-assay CV of 6.6% and 11.5%)
and fibrinogen levels (intra-assay CV of 11.1%) were mea-
sured by refractometry [21].
Metabolite quantification
The Absolute-IDQ platform (Kit p150, Biocrates, Innsbruck,
Austria) was employed for targeted metabolite profiling
as described by the manufacturer. This platform detects
a total of 163 metabolites, including 14 amino acids, 41
acylcarnitines (Cx:y), hydroxylacylcarnitines [C (OH) x:y]
and dicarboxylacylcarnitines (Cx:y-DC), the sum of hex-
oses, 15 sphingomyelins (SMx:y) and sphingomyelin deriva-
tives [SM (OH) x:y], as well as 15 lyso-phosphatidylcholines
and 77 phosphatidylcholines (PC). The latter were further
differentiated with respect to the presence of ester (“a”)
and ether (“e”) bonds in the glycerol moiety, whereby
two letters “aa” (=diacyl) and “ae” (=acyl-alkyl) indicate
that two glycerol positions are bound to a fatty acid
residue, while a single letter “a” (=acyl) indicates the
presence of a single fatty acid residue. The lipid side
chain composition is abbreviated with “Cx:y”, whereby
“x” denotes the number of carbons in the side chain
and “y” the number of double bonds. A detailed list of
all analyzed metabolites is presented elsewhere [22].
The assay was performed on a double-filter 96-well
plate containing stable isotope-labeled internal standards.
All chemicals were from Sigma-Aldrich (Steinheim,
Germany). Briefly, the serum samples (10 μl) were pipet-
ted onto the upper filter spots of the 96-well plate and
Table 1 Periparturient dairy cows of the study, their disease, mean age (years) and lactation stage (weeks postpartum)
Group N Diseases (number of affected animals) Age years ± S.D. Lactation weeks ± S.D.
1 6 Displaced abomasum (3), bronchopneumonia (2), ileus (1) 7.2 ± 1.8 1.8 ± 0.7
2 10 Low grade hepatic lipidosis (10) and, in addition, displaced abomasum (3),
bronchopneumonia (1), retained placenta (1), mastitis (1)
5.1 ± 1.7 2.9 ± 2.1
3 7 Medium grade hepatic lipidosis (7) and, in addition, displaced abomasum (2)
and bronchopneumonia (1)
5.2 ± 2.4 2.3 ± 0.7
4 5 Severe hepatic lipidosis (5) and, in addition, displaced abomasum (2) and
bronchopneumonia (1)
5.5 ± 0.8 4.2 ± 1.3
The 28 animals were from 27 different farms, i.e., only two cows of group 3 came from the same farm.
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phenylisothiocyanate was added for derivatization of
amino acids. Next, the samples were dried under a nitro-
gen stream, extracted with 5 mM ammonium acetate in
methanol, centrifuged through the filter membranes and
diluted with chromatographic solvent. Finally, the extracts
were injected into the Agilent 1100 Series HPLC (operated
by the Analyst 1.4.2 software) coupled to an API 4000
triple quadrupole mass spectrometer (ABSciex) through
electrospray ionization. A standard flow injection with
two 20-μl aliquots (one for the positive and one for the
negative ion mode) was applied to all measurements.
Quantification was achieved by multiple reaction monitor-
ing (MRM) detection using the MetIQTM software pack-
age, which is an integral part of the AbsoluteIDQ kit. This
method is in conformity with the proof of reproducibility
outlined in the Guidance for Industry–Bioanalytical
Method Validations issued by the FDA [23]. The analytical
variability, in terms of intra-assay coefficient of variance
(CV), was 7.3%. For statistical analyses, only metabolites
were chosen for which all values exceeded the detection
limit, thus restricting the profile to a total of 80 metabolites
(5 amino acids, 62 phosphatidylcholines, 8 sphingomyelins
and 5 sphingomyelin derivatives). These metabolites were:
glutamine, glycine, phenylalanine, proline, serine, PC aa
C24:0, PC aa C26:0, PC aa C28:1, PC aa C30:0, PC aa
C30:2, PC aa C32:0, PC aa C32:1, PC aa C32:2, PC aa
C32:3, PC aa C34:1, PC aa C34:2, PC aa C34:3,PC aa
C34:4, PC aa C36:1, PC aa C36:2, PC aa C36:3, PC aa
C36:4, PC aa C36:5, PC aa C36:6, PC aa C38:3, PC aa
C38:4, PC aa C38:5, PC aa C38:6, PC aa C40:2, PC aa
C40:3, PC aa C40:4, PC aa C40:5, PC aa C40:6, PC aa
C42:1, PC aa C42:2, PC ae C30:1, PC ae C30:2, PC ae
C32:1, PC ae C32:2, PC ae C34:0, PC ae C34:1, PC ae
C34:2, PC ae C34:3, PC ae C36:0, PC ae C36:1, PC ae
C36:2, PC ae C36:3, PC ae C36:5, PC ae C38:1, PC ae
C38:2, PC ae C38:3, PC ae C38:4, PC ae C38:5, PC ae
C38:6, PC ae C40:2, PC ae C40:3, PC ae C40:5, PC ae
C40:6, PC ae C42:2, PC ae C42:3, lysoPC a C16:0, lysoPC a
C16:1, lysoPC a C18:0, lysoPC a C18:1, lysoPC a C26:0,
lysoPC a C28:0, lysoPC a C28:1, SM C16:0, SM C16:1, SM
C18:0, SM C18:1, SM C24:0, SM C24:1, SM C26:0, SM
C26:1, SM (OH) C14:1, SM (OH) C16:1, SM (OH) C22:1,
SM (OH) C22:2 and SM (OH) C24:1.
The mass spectrometry data of this study were deposited
in the PRIDE database using the mzML format (accession
number 1-20130722-115242).
Statistics
A multivariate processing of metabolomics data was car-
ried out using the statistical package SPSS + (version
12.0.2G). First, each sample was standardized to the
mean of the control (set to 100%) and normalized using
z-score values. Then, a MANOVA (multivariate analysis
of variance) was used for compound selection [24,25].
All 29 variables that showed a significant group difference
(p ≤ 0.006) were selected for a principal component
analysis-linear discriminant function model. The principal
component analysis (without rotation) was performed to
achieve data reduction and the resulting factors were used
for a post-hoc linear discriminant analysis as described else-
where [26] for group separation. This linear discriminant
analysis model resulted in three factors accounting for 100%
of the observed variance in the system. The linear functions
for these three discriminant factors were: F(x1) = 1.45 •
VAR1 + 2.67 • VAR2 – 0.99 • VAR3 – 2.263 • VAR4 + 1.11 •
VAR5 + 0.298 • VAR6 + 1.15 • VAR7+ 1.05 • VAR8 – 0.94 •
VAR9 – 0.083 • VAR10 – 1.08 • VAR11; F(x2) = – 1.19 •
VAR1 + 0.59 • VAR2 + 0.024 • VAR3 – 0.774 • VAR4 – 0.72
• VAR5+ 0.18 • VAR6 – 0.46 • VAR7 + 0.71 • VAR8 + 0.32 •
VAR9 + 0.42 • VAR10 + 0.61 • VAR11; F(x3) = − 0.113 •
VAR1 – 0.22 • VAR2+ 0.57 • VAR3 – 0.120 • VAR4 – 0.11 •
VAR5 – 0.22 • VAR6+ 0.57 • VAR7 – 0.21 • VAR8 + 0.41 •
VAR9 – 0.26 • VAR10 + 0.64 • VAR11. The discriminant
function F(x1) separates the fatty liver group 3 from
control animals (group 1) as well as from group 2. F(x1)
also discriminates between groups 1 and 2. The dis-
criminant function F(x2) separates controls (group 1)
from group 4, whereas F(x3) discriminates between
groups 2 and 4. A detailed description of the equations
for VAR1 to VAR11 is included [see Additional file 1].
By this method, all samples were classified correctly in
the corresponding hepatic lipidosis groups defined by
histopathological findings. The performance of this dis-
criminant model was subsequently verified by applying
the “leave-one-out” cross-validation formalism [27,28].
Results
A total of 28 diseased cows (from 27 different farms)
were tested to identify metabolic biomarkers distinguish-
ing hepatic lipidosis from other peripartal disorders. Fol-
lowing liver biopsy and histologic examination, the 28
early lactating cows were partitioned into 4 categories:
group 1 (constituting the reference group of 6 animals
displaying no hepatic lipidosis), group 2 (10 animals with
low grade hepatic lipidosis), group 3 (7 animals with
medium grade hepatic lipidosis) and group 4 (5 animals
with severe hepatic lipidosis). The animals of group 1
were presented to the veterinary hospital because of dis-
placed abomasum, bronchopneumonia or ileus. Some of
these disorders, besides retained placenta or mastitis,
were also encountered in the animals of groups 2–4 in
addition to their different stages of hepatic lipidosis
(Table 1).
Clinical chemistry analysis
In dairy cows, the excess storage of triacylglycerols in the
liver causes progressive hepatocyte damage and, conse-
quently, membrane leakage that results in the increased
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release of liver enzymes and bile constituents into the
blood [2,9]. However, clinical chemical parameters like as-
partate aminotransferase (ASAT), γ-glutamyl transferase
(GGT), glutamate dehydrogenase (GLDH), sorbitol de-
hydrogenase (SDH) and bilirubin levels in the blood, being
non-specific biomarkers of organ injury, were already ele-
vated in the reference group 1 of cows whose biopsies did
not reveal typical features of hepatic lipidosis but that
were admitted to the veterinary hospital for other disor-
ders (Table 2). As a general trend, some of these conven-
tional clinical chemistry values (GGT, GLDH and SDH)
further increased from group 1 to group 4 (Figure 1), but
without being able to discriminate between distinct disease
etiologies. Conversely, we observed decreasing plasma fi-
brinogen concentrations correlating with the gradually en-
hanced severity of fatty liver disease in groups 2–4 relative
to group 1 (Figure 2A), although the overall protein level
remained in the normal range (Figure 2B). In summary,
these selected clinical chemistry parameters fail to display
specificity for the appearance of hepatic lipidosis and,
hence, are not sufficient to confirm the diagnosis of this
particular disease.
Metabolomic analysis
To expand the spectrum of biomarkers that accompany
hepatic lipidosis in dairy cows, the AbsoluteIDQ system
was applied in conjunction with triple quadrupole mass
spectrometry to compare the serum metabolites of animals
that did not show any lipid storage in liver cells (reference
group 1) and the corresponding groups 2–4 displaying
various stages of the syndrome. The AbsoluteIDQ metabo-
lomic platform allows for the accurate identification and
quantitative measurement of 163 endogenous metabolites
from different compound classes, including amino acids,
carbohydrates, carnitines, sphingolipids and phosphatidyl-
cholines [29-31]. A multivariate statistical model revealed
29 metabolites, listed in Table 3, who could be used to sep-
arate the hepatic lipidosis groups 2 to 4 from the reference
group 1. To graphically illustrate the clear separation be-
tween groups achieved by this set of metabolic endpoints,
the data were subjected to principal component and linear
discriminant analyses (Figure 3). Using the loading fac-
tors for linear discriminant function 1 outlined in the
“Methods” section, we identified 6 phosphatidylcholines
that contributed the most to the observed separation
and could therefore be regarded as a promising predict-
ive biomarkers of hepatic lipidosis: PC aa C30:2, PC aa
C32:2, PC aa C36:3, PC aa C38:3, PC aa C36:4 and PC
ae C36:2).
Two of the 29 discriminating metabolites turned out
to be the amino acids glycine (Figure 4A) and glutamine
(Figure 4B) with diminished blood levels in the diseased
animals of groups 2–4 relative to group 1. However, the
majority of metabolites able to discriminate between the
reference group 1 and the different stages of fatty liver
disease were phosphatidylcholines (PC), i.e. the diacyl-
phosphatidylcholines PC aa C30:2, PC aa C32:2, PC aa
C36:2, PC aa C36:3, PC aa C36:4, PC aa C38:3, PC aa
C38:4, PC aa C38:6, PC aa C40:2, PC aa C40:3, PC aa
C40:4 and PC aa C42:2, as well as the acyl-alkyl-
phosphatidylcholines PC ae C34:1, PC ae C36:2, PC ae
C36:3, PC ae C38:2, PC ae C38:3, PC ae C38:4, PC ae
C40:2 and PC ae C40:3 (Table 3). Additional discriminat-
ing components in the tested sera included the sphingo-
myelins SM C18:0 (the only saturated lipid), SM C18:1,
SM C24:1 and SM C26:1 as well as the hydroxy-
sphingomyelines SM(OH) C22:1, SM (OH) C22:2 and SM
(OH) C24:1. As exemplified by PC aa C40:3 in Figure 5A,
generally these metabolites showed lower levels in cows
with fatty liver disease (groups 2–4) than in the refer-
ence animals of group 1. Exceptions were the diacyl-
phosphatidylcholines PC aa C30:2 and PC aa C32:2, for
which higher levels could be measured in cows with
hepatic lipidosis compared to the reference animals
(Figures 5B and 5C). All lyso-phosphatidylcholines and
the sum of hexoses did not show any significant differ-
ence between the four groups of early lactating cows.
Discussion
All cows of this study displayed increased serum levels
of enzymes and bilirubin that are generally indicative of
liver damage or injuries to other tissues like cardiac or
skeletal muscle [21]. Therefore, these canonical clinical
chemistry values were unable to distinguish between
hepatic lipidosis and other peripartal disorders. A novel
observation of this study is the reduction of the fibrino-
gen serum conten in periparturient cows suffering from
hepatic lipidosis. As this fibrin precursor is produced in
Table 2 Key clinical chemistry values in the blood of the reference group 1 (without hepatic lipidosis)
Parameter Normal range Measured values in the reference animals (group 1)
Median Mean Standard error of the mean
ASAT 57-103 U/l 568 U/l 600 U/l 202 U/l
GGT 13-32 U/l 34 U/l 48 U/l 16 U/l
GLDH 4-18.2 U/l 73 U/l 164 U/l 86 U/l
SDH 4-7.4 U/l 19 U/l 57 U/l 33 U/l
Total bilirubin 1.5-2.9 μmol/l 14.4 μmol/l 18.6 μmol/l 7.0 μmol/l
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the liver, its lower level may represent a direct conse-
quence of hepatocyte dysfunction due to excessive lipid
deposition, but may also result from coagulopathy linked
to liver disease [32]. In fact, hyperfibrinolysis leading to
hypofibrinogenemia is known to arise from a poor hepatic
clearance of tissue plasminogen activator or from reduced
hepatic production of fibrinolysis inhibitors. However,
there was no clinically apparent coagulopathy in the cows
of the current study.
In view of the lack of specificity of canonical clinical
chemistry values indicative of hepatic lipidosis, including
the aforementioned fibrinogen levels, the purpose of our
pilot study was to establish a targeted metabolomics
platform to discover correlations between this disorder
and molecular changes detectable in blood samples of
periparturient dairy cows. Instead of comparing groups
of healthy and diseased animals, we employed a more
practical situation encountered in the veterinary hospital
environment, where hepatic lipidosis has to be differenti-
ated from other peripartal diseases. As a consequence, the
reference group in our study consisted of animals whose
clinical chemistry parameters revealed considerable injur-
ies to the liver or other tissue damages (Figure 1). Never-
theless, a targeted metabolomics approach led to the
Figure 1 Comparison of clinical chemistry parameters between the reference animals of group 1 (without hepatic lipidosis) and
groups 2–4 (with progressive stages of hepatic lipidosis). The parameters examined were (A) Aspartate aminotransferase (ASAT), (B) γ-glutamyl
transferase (GGT), (C) glutamate dehydrogenase (GLDH), (D) Sorbitol dehydrogenase (SDH) and (E) Bilirubin. P ≤ 0.05 indicates a significant reduction of
ASAT activity in the animals of group 2 relative to group 1; n.s., not significant.
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Figure 2 Level of fibrinogen in plasma and total plasma protein concentration in the different groups of dairy cows (mean values of
5–10 animals). (A) Plasma fibrinogen. (B) Total plasma protein. Group 1: no hepatic lipidosis; groups 2–4: progressive stages of hepatic lipidosis.
The P values indicate significant differences with the reference group 1; n.s., not significant.
Table 3 List of metabolites with significant changes between the groups upon MANOVA (normalized mean values ± S.D.)
Metabolite Category Group 1 Group 2 Group 3 Group 4 P value
Glutamine Amino acids 100 ± 28.7 50.1 ± 24.3 49.6 ± 13.4 30.8 ± 5.9 ≤ 0.0004
Glycine 100 ± 21.9 66.6 ± 23.4 52.0 ± 11.8 49.0 ± 9.3 ≤ 0.0004
PC aa C30:2 Phosphatidyl-cholines 100 ± 15.7 87.7 ± 24.1 118.4 ± 32.9 139.0 ± 16.2 0.004
PC aa C32:2 100 ± 17.3 81.7 ± 38.4 121.0 ± 62.0 159.0 ± 39.7 0.002
PC aa C36:2 100 ± 15.0 66.2 ± 33.8 52.8 ± 13.9 40.8 ± 10.8 0.002
PC aa C36:3 100 ± 15.2 58.4 ± 20.7 50.5 ± 14.4 50.0 ± 13.0 ≤ 0.0004
PC aa C36:4 100 ± 11.5 60.8 ± 21.7 50.2 ± 13.4 51.6 ± 14.4 ≤ 0.0004
PC aa C38:3 100 ± 14.5 58.3 ± 20.7 49.1 ± 14.7 45.9 ± 10.3 ≤ 0.0004
PC aa C38:4 100 ± 11.7 70.7 ± 22.2 55.3 ± 21.0 59.5 ± 14.9 0.002
PC aa C38:6 100 ± 15.5 70.1 ± 16.0 79.1 ± 12.4 78.5 ± 12.7 0.006
PC aa C40:2 100 ± 17.7 70.6 ± 39.5 51.0 ± 21.4 34.1 ± 12.0 0.004
PC aa C40:3 100 ± 18.3 45.0 ± 18.4 40.1 ± 12.6 32.3 ± 6.9 ≤ 0.0004
PC aa C40:4 100 ± 10.6 68.0 ± 26.6 55.1 ± 17.5 49.2 ± 10.2 0.001
PC aa C42:2 100 ± 11.2 76.4 ± 35.9 64.7 ± 25.9 36.6 ± 9.4 0.005
PC ae C34:1 100 ± 12.7 71.4 ± 23.9 62.0 ± 10.3 58.1 ± 10.6 0.001
PC ae C36:2 100 ± 15.8 63.7 ± 24.5 58.6 ± 10.6 55.7 ± 12.1 0.001
PC ae C36:3 100 ± 17.8 61.3 ± 14.3 58.3 ± 12.8 60.8 ± 8.8 ≤ 0.0004
PC ae C38:2 100 ± 14.8 73.9 ± 31.8 54.3 ± 16.6 42.6 ± 7.5 0.001
PC ae C38:3 100 ± 11.7 56.9 ± 18.2 50.0 ± 15.8 41.3 ± 8.0 ≤ 0.0004
PC ae C38:4 100 ± 17.8 67.4 ± 14.1 68.8 ± 17.1 63.7 ± 14.2 0.002
PC ae C40:2 100 ± 7.6 62.5 ± 17.4 62.9 ± 9.9 57.1 ± 12.6 ≤ 0.0004
PC ae C40:3 100 ± 11.5 61.7 ± 13.2 65.1 ± 10.3 75.2 ± 10.2 ≤ 0.0004
SM C18:0 Sphingomyelins 100 ± 22.4 67.2 ± 34 49.2 ± 48.6 14.2 ± 20.5 0.003
SM C18:1 100 ± 21.9 66.9 ± 33.3 53.5 ± 20.2 34.0 ± 10.2 0.002
SM C24:1 100 ± 13.7 52.2 ± 16.5 62.3 ± 15.5 47.8 ± 9.7 ≤ 0.0004
SM C26:1 100 ± 14.8 45.9 ± 16.3 57.8 ± 12.9 42.2 ± 7.9 ≤ 0.0004
SM (OH) C22:1 Hydroxy-sphingomyelins 100 ± 13.0 52.1 ± 18.1 68.8 ± 16.6 67.7 ± 12.8 ≤ 0.0004
SM (OH) C22:2 100 ± 10.6 48.0 ± 15.4 56.5 ± 15.9 55.6 ± 11.9 ≤ 0.0004
SM (OH) C24:1 100 ± 6.0 56.3 ± 21.8 74.2 ± 15.2 58.0 ± 13.9 ≤ 0.0004
Group 1, without hepatic lipidosis; groups 2–4, progressive stages of hepatic lipidosis.
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identification of an endogenous molecular profile that ap-
pears to be specific for hepatic lipidosis, thus distinguish-
ing this disease from other peripartal problems. Two of
the 29 discriminating metabolites were the amino acids
glycine and glutamine that have already been linked to
metabolic disorders and chronic inflammatory conditions
[33-37], which are both key hallmarks of hepatic lipidosis.
From the discriminant function coefficients of the vari-
ables we found, however, that the following six phos-
phatidylcholines contributed the most to the observed
separation and could therefore be regarded as a poten-
tial set of predictive biomarkers of hepatic lipidosis: PC
aa C30:2 (Figure 5B), PC aa C32:2 (Figure 5C), PC aa
C36:3, PC aa C38:3, PC aa C36:4 and PC ae C36:2. Al-
though changes of phosphatidylcholine and sphingomyelin
blood levels have previously been associated with meta-
bolic disorders [38] or chronic liver diseases [39], the pos-
sible link of the listed phosphatidylcholines with hepatic
lipidosis is intriguing. Because they constitute an important
precursor for the synthesis of hepatic triacylglycerols [40],
phosphatidylcholines may be reduced in peripartal dairy
cows as a direct consequence of an enhanced triacylglyc-
erol production [2,7,8]. Conversely, hepatic phosphatidyl-
cholines are required for the assembly and secretion of
VLDL implying that a reduced phosphatidylcholine con-
tent may aggravate the accumulation of triacylglycerols in
the liver by limiting their export from hepatocytes [41]. In
our study, the observed changes of lipid levels involve an
increase of those phosphatidylcholines that carry relatively
short fatty acid moieties (PC aa C30:2 and PC aa C32:2),
whereas the quantity of phosphatidylcholines containing
larger fatty acid components (≥34 carbons) was reduced.
This shift in phosphatidylcholine composition suggests a
possible prophylactic or therapeutic approach based on the
modulation of phosphatidylcholine biosynthesis by appro-
priate feed supplementation [42]. In any case, the observed
shift in phosphatidylcholine distribution is a novel finding
that needs to be further investigated mechanistically to
understand if it has a causal relationship with the disease
or rather constitutes a consequence thereof.
Figure 3 Combined principal component and linear discriminant analysis. This model reveals that 29 endogenous metabolites, in conjunction,
distinguish dairy cows with different stages of hepatic lipidosis (groups 2–4) from reference animals (group 1) lacking the characteristic lipid deposition
in their liver. The centroid, or center of mass, were computed from the coordinates of all points in each group. The linear functions for the two main
discriminant factors [F (x1) and F (x2)] are laid down in the “Methods” section.
Figure 4 Typical examples of metabolites whose concentrations decreased with progressing hepatic lipidosis. Group 1: no hepatic lipidosis;
groups 2–4: different stages of hepatic lipidosis (mean values of 5–10 animals). (A) Level of glycine in the serum of dairy cows. (B) Level of glutamine
in the serum of dairy cows. The P values indicate significant differences with the reference group 1.
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Conclusion
New biomarkers of hepatic lipidosis are urgently needed
to facilitate diagnostic procedures, identify distinct stages
of the disease, monitor the response to treatment regi-
mens and allow for the design of prevention strategies. An
important new paradigm in biomarker discovery research
is to consider entire sets of molecular changes, instead of
single parameters, that correlate with a particular disease
[43]. In the present study, we have exploited the fact that
serum metabolite concentrations provide a direct readout
of disturbed biochemical pathways [29]. This approach led
us to employ multivariate statistics, based on 29 key me-
tabolites, to recognize deranged metabolic patterns that
correlate specifically with distinct stages of hepatic lipid-
osis in dairy cows, thus distinguishing this disease from
other peripartal disorders. Future studies with larger ani-
mal groups are needed to confirm the findings of this
study, to validate the newly identified metabolic profile
and explore its clinical application to the diagnosis and
treatment of diseased animals.
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Figure 5 Serum concentration of diacyl-phosphatidylcholines
(mean values of 5–10 animals). (A) Example of metabolite (PC aa
C40:3) whose concentration decreased with progressing hepatic
lipidosis. Group 1: no hepatic lipidosis; groups 2–4: different stages
of hepatic lipidosis. (B) and (C) Diacyl-phosphatidylcholines whose
serum concentrations increased with progressing hepatic lipidosis. The
P values indicate significant differences with the reference group 1;
n.s., not significant.
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